Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film GlobeNewswire - Mon Mar 30, 6:00AM CDT

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026 Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designs Final FDA meeting minutes expected...

AQST : 4.04 (+0.50%)
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026 PR Newswire - Sun Mar 29, 7:43AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.04 (+0.50%)
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire - Fri Mar 27, 4:28PM CDT

NEW YORK , March 27, 2026 /PRNewswire/ --

AQST : 4.04 (+0.50%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST PR Newswire - Thu Mar 26, 9:00AM CDT

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  ...

AQST : 4.04 (+0.50%)
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt PR Newswire - Thu Mar 26, 8:00AM CDT

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA?

AQST : 4.04 (+0.50%)
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky PR Newswire - Wed Mar 25, 8:00AM CDT

Wall Street Reassessment: Analyst Opinion Evolution on AQST

AQST : 4.04 (+0.50%)
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky Business Wire - Tue Mar 24, 3:00PM CDT

Important Information Regarding Section 20(a) Individual Liability Claims

AQST : 4.04 (+0.50%)
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm PR Newswire - Tue Mar 24, 8:00AM CDT

NEW YORK , March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).

AQST : 4.04 (+0.50%)
Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action PR Newswire - Mon Mar 23, 9:31PM CDT

SAN DIEGO , March 23, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics,...

AQST : 4.04 (+0.50%)
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 PR Newswire - Sun Mar 22, 8:03AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.04 (+0.50%)

Barchart Exclusives

Meta Platforms Just Made Entergy a Top Stock to Buy... and It Pays a 2.49% Dividend Barchart - 1 hour ago
Meta’s decision to fully fund seven new natural gas plants, 240 miles of 500 kV transmission, batteries, and up to 2.5 GW of solar to power its giant Louisiana AI data center effectively gives Entergy a multi‑decade growth runway with limited bill pressure on other customers, which is a rare setup for a regulated utility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.